Journal of International Oncology ›› 2022, Vol. 49 ›› Issue (10): 627-629.doi: 10.3760/cma.j.cn371439-20220531-00125
• Reviews • Previous Articles Next Articles
Xu Kai, Wen Gang(
), Li Rui, Tian Yuan
Received:2022-05-31
Revised:2022-06-07
Online:2022-10-08
Published:2022-12-01
Contact:
Wen Gang
E-mail:wengang@medmail.com
Xu Kai, Wen Gang, Li Rui, Tian Yuan. Research progress on the prognostic value of the ratio of lymphocytes to C-reactive protein in digestive system neoplasms[J]. Journal of International Oncology, 2022, 49(10): 627-629.
| [1] |
Suarez-Carmona M, Lesage J, Cataldo D, et al. EMT and inflammation: inseparable actors of cancer progression[J]. Mol Oncol, 2017, 11(7): 805-823. DOI: 10.1002/1878-0261.12095.
doi: 10.1002/1878-0261.12095 pmid: 28599100 |
| [2] |
Khandia R, Munjal A. Interplay between inflammation and cancer[J]. Adv Protein Chem Struct Biol, 2020, 119: 199-245. DOI: 10.1016/bs.apcsb.2019.09.004.
doi: S1876-1623(19)30069-0 pmid: 31997769 |
| [3] |
Yu Y, Wu Z, Shen Z, et al. Preoperative C-reactive protein-to-albumin ratio predicts anastomotic leak in elderly patients after curative colorectal surgery[J]. Cancer Biomarkers, 2020, 27(3): 295-302. DOI: 10.3233/CBM-190470.
doi: 10.3233/CBM-190470 pmid: 31658046 |
| [4] |
Stojkovic Lalosevic M, Pavlovic Markovic A, Stankovic S, et al. Combined diagnostic efficacy of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and mean platelet volume (MPV) as biomarkers of systemic inflammation in the diagnosis of colorectal cancer[J]. Disease Markers, 2019, 2019: 6036979. DOI: 10.1155/2019/6036979.
doi: 10.1155/2019/6036979 |
| [5] |
Kamonvarapitak T, Matsuda A, Matsumoto S, et al. Preoperative lymphocyte-to-monocyte ratio predicts postoperative infectious complications after laparoscopic colorectal cancer surgery[J]. Int J Clin Oncol, 2020, 25(4): 633-640. DOI: 10.1007/s10147-019-01583-y.
doi: 10.1007/s10147-019-01583-y pmid: 31781993 |
| [6] |
杨银静, 李桂香, 唐敏. 纤维蛋白原、NLR及F-NLR评分在胃癌中的研究进展[J]. 国际肿瘤学杂志, 2021, 48(7): 433-435. DOI: 10.3760/cma.j.cn371439-20201230-00083.
doi: 10.3760/cma.j.cn371439-20201230-00083 |
| [7] |
Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-C-reactive protein ratio as promising new marker for predicting surgical and oncological outcomes in colorectal cancer[J]. Ann Surg, 2020, 272(2): 342-351. DOI: 10.1097/SLA.0000000000003239.
doi: 10.1097/SLA.0000000000003239 pmid: 32675548 |
| [8] |
Yildirim M, Koca B. Lymphocyte C-reactive protein ratio: a new biomarker to predict early complications after gastrointestinal oncologic surgery[J]. Cancer Biomarkers, 2021, 31(4): 409-417. DOI: 10.3233/CBM-210251.
doi: 10.3233/CBM-210251 pmid: 34151845 |
| [9] |
Suzuki S, Akiyoshi T, Oba K, et al. Comprehensive comparative analysis of prognostic value of systemic inflammatory biomarkers for patients with stage Ⅱ/Ⅲ colon cancer[J]. Ann Surg Oncol, 2020, 27(3): 844-852. DOI: 10.1245/s10434-019-07904-9.
doi: 10.1245/s10434-019-07904-9 |
| [10] |
Lu L H, Zhong C, Wei W, et al. Lymphocyte-C-reactive protein ratio as a novel prognostic index in intrahepatic cholangiocarcinoma: a multicentre cohort study[J]. Liver Int, 2021, 41(2): 378-387. DOI: 10.1111/liv.14567.
doi: 10.1111/liv.14567 |
| [11] |
Takeuchi M, Kawakubo H, Hoshino S, et al. Lymphocyte-to-C-reactive protein ratio as a novel marker for predicting oncological outcomes in patients with esophageal cancer[J]. World J Surg, 2021, 45(11): 3370-3377. DOI: 10.1007/s00268-021-06269-z.
doi: 10.1007/s00268-021-06269-z pmid: 34383091 |
| [12] |
Yugawa K, Itoh S, Yoshizumi T, et al. Lymphocyte-C-reactive protein ratio as a prognostic marker associated with the tumor immune microenvironment in intrahepatic cholangiocarcinoma[J]. Int J Clin Oncol, 2021, 26(10): 1901-1910. DOI: 10.1007/s10147-021-01962-4.
doi: 10.1007/s10147-021-01962-4 pmid: 34117554 |
| [13] |
Lu LH, Wei W, Li SH, et al. The lymphocyte-C-reactive protein ratio as the optimal inflammation-based score in patients with hepatocellular carcinoma underwent TACE[J]. Aging (Albany, NY), 2021, 13(4): 5358-5368. DOI: 10.18632/aging.202468.
doi: 10.18632/aging.202468 |
| [14] |
Cheng CB, Zhang QX, Zhuang LP, et al. Prognostic value of lymphocyte-to-C-reactive protein ratio in patients with gastric cancer after surgery: a multicentre study[J]. Jpn J Clin Oncol, 2020, 50(10): 1141-1149. DOI: 10.1093/jjco/hyaa099.
doi: 10.1093/jjco/hyaa099 |
| [15] |
Okugawa Y, Toiyama Y, Yamamoto A, et al. Lymphocyte-to-C-reactive protein ratio and score are clinically feasible nutrition-inflammation markers of outcome in patients with gastric cancer[J]. Clin Nutr, 2020, 39(4): 1209-1217. DOI: 10.1016/j.clnu.2019.05.009.
doi: S0261-5614(19)30220-1 pmid: 31155370 |
| [16] |
Angin YS, Yildirim M, Dasiran F, et al. Could lymphocyte to C-reactive protein ratio predict the prognosis in patients with gastric cancer?[J]. ANZ J Surg, 2021, 91(7-8): 1521-1527. DOI: 10.1111/ans.16913.
doi: 10.1111/ans.16913 pmid: 33956378 |
| [17] |
Davies JM, Goldberg RM. Treatment of metastatic colorectal cancer[J]. Semin Oncol, 2011, 38(4): 552-560. DOI: 10.1053/j.seminoncol.2011.05.009.
doi: 10.1053/j.seminoncol.2011.05.009 pmid: 21810514 |
| [18] |
Nakamura Y, Shida D, Boku N, et al. Lymphocyte-to-C-reactive protein ratio is the most sensitive inflammation-based prognostic score in patients with unresectable metastatic colorectal cancer[J]. Dis Colon Rectum, 2021, 64(11): 1331-1341. DOI: 10.1097/DCR.0000000000002059.
doi: 10.1097/DCR.0000000000002059 pmid: 34623347 |
| [19] |
Iseda N, Itoh S, Yoshizumi T, et al. Lymphocyte-to-C-reactive protein ratio as a prognostic factor for hepatocellular carcinoma[J]. Int J Clin Oncol, 2021, 26(10): 1890-1900. DOI: 10.1007/s10147-021-01985-x.
doi: 10.1007/s10147-021-01985-x pmid: 34251555 |
| [20] |
Yugawa K, Maeda T, Kinjo N, et al. Prognostic impact of lymphocyte-C-reactive protein ratio in patients who underwent surgical resection for hepatocellular carcinoma[J]. J Gastrointest Surg, 2022, 26(1): 104-112. DOI: 10.1007/s11605-021-05085-z.
doi: 10.1007/s11605-021-05085-z |
| [21] |
Zhang YF, Lu LH, Zhong C, et al. Prognostic value of the pre-operative lymphocyte-C-reactive protein ratio in hepatocellular carcinoma patients treated with curative intent: a large-scale multicentre study[J]. J Inflamm Res, 2021, 14: 2483-2495. DOI: 10.2147/JIR.S311994.
doi: 10.2147/JIR.S311994 |
| [22] |
Yao WY, Wu XS, Liu SL, et al. Preoperative lymphocyte to C-reactive protein ratio as a new prognostic indicator in patients with resectable gallbladder cancer[J]. Hepatobiliary Pancreat Dis Int, 2022, 21(3): 267-272. DOI: 10.1016/j.hbpd.2021.08.006.
doi: 10.1016/j.hbpd.2021.08.006 |
| [1] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331. |
| [2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337. |
| [3] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266. |
| [4] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279. |
| [5] | Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197. |
| [6] | Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209. |
| [7] | Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222. |
| [8] | Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150. |
| [9] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180. |
| [10] | Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185. |
| [11] | Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82. |
| [12] | Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104. |
| [13] | Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64. |
| [14] | Wang Xiao, Li Ying, Luo Yujie, Jin Shu. Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model [J]. Journal of International Oncology, 2023, 50(8): 463-469. |
| [15] | Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
